Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for Naproxen/Esomeprazole

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Aug 31, 2027 · 369 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Naproxen/Esomeprazol (ATC-Code nach WHO: M01AE52)

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

The structured data marks electronic submission as not allowed and submission method as not allowed, while the XML noti...

Key participation conditions are contained in documents not provided in the extracted text, including 'Anschreiben', 'E...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Non-exclusive rebate agreement for pharmaceutical products containing Naproxen/Esomeprazole (ATC M01AE52).
  • Open-House model: contract conclusion is open to all interested pharmaceutical companies that meet and accept the participation conditions.
Pokaż pełne podsumowanie

This is an Open-House supply arrangement for non-exclusive pharmaceutical rebate agreements for Naproxen/Esomeprazole (ATC M01AE52) with AOK PLUS. The notice states that any interested pharmaceutical company meeting the participation conditions may join during the participation period, with no individual negotiations and no exclusivity. The contract term ends no later than 31.08.2027. Participation documents are available via DTVP, but the extracted procurement documents were not provided, so document-specific requirements could not be fully analyzed.

Ryzyka

The structured data marks electronic submission as not allowed and submission method as not allowed, while the XML noti...

Key participation conditions are contained in documents not provided in the extracted text, including 'Anschreiben', 'E...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.

Eligibility

  • Submission of the completed declaration of non-existence of exclusion grounds under §§ 123, 124 GWB is required.

Administrative

  • The company must meet and accept the participation conditions in the documents.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for Naproxen/Esomeprazole

Single lot for a non-exclusive rebate agreement concerning the pharmaceutical product Naproxen/Esomeprazole (ATC M01AE52). Scope is supply of pharmaceutical products under an Open-House model. Place of performance is Dresden, Germany. The lot is a framework agreement/open-house style arrangement with no guaranteed minimum purchase volume and no exclusivity. Lot information comes from structured data and XML notice.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Aug 2025 - Aug 2027

Kategoria

Pharmaceutical products

Termin

Deadline Aug 31, 2027

Szczegóły zamówienia

Data publikacji
08 Jul 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
446354-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3